Evidence map›Paper›PMID 33750814›Full record

ArticleScientific reports2021

Metallothionein-3 promotes cisplatin chemoresistance remodelling in neuroblastoma.

Miguel Angel Merlos Rodrigo, Hana Michalkova, Vladislav Strmiska, Berta Casar, Piero Crespo, Vivian de Los Rios, J Ignacio Casal, Yazan Haddad, Roman Guran, Tomas Eckschlager and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Recent Advances in Anticancer Research of Osmium and Rhodium Complexes.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Can Cisplatin Therapy Be Improved? Pathways That Can Be Targeted.International journal of molecular sciences · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Extending the Applicability ofFrontiers in oncology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Miguel Angel Merlos RodrigoDepartment of Chemistry and Faculty of AgriSciences, Mendel University in Brno, Zemedelska 1, 613 00, Brno, Czech Republic.
Hana MichalkovaDepartment of Chemistry and Faculty of AgriSciences, Mendel University in Brno, Zemedelska 1, 613 00, Brno, Czech Republic.
Vladislav StrmiskaDepartment of Chemistry and Faculty of AgriSciences, Mendel University in Brno, Zemedelska 1, 613 00, Brno, Czech Republic.
Berta CasarInstituto de Biomedicina Y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, 39011, Santander, Spain.
Piero CrespoInstituto de Biomedicina Y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Cantabria, 39011, Santander, Spain.
Vivian de Los RiosFunctional Proteomics, Department of Cellular and Molecular Medicine and Proteomic Facility, Centro de Investigaciones Biológicas (CIB-CSIC), Ramiro de Maeztu 9, 28040, Madrid, Spain.
J Ignacio CasalFunctional Proteomics, Department of Cellular and Molecular Medicine and Proteomic Facility, Centro de Investigaciones Biológicas (CIB-CSIC), Ramiro de Maeztu 9, 28040, Madrid, Spain.
Yazan HaddadDepartment of Chemistry and Faculty of AgriSciences, Mendel University in Brno, Zemedelska 1, 613 00, Brno, Czech Republic.
Roman GuranDepartment of Chemistry and Faculty of AgriSciences, Mendel University in Brno, Zemedelska 1, 613 00, Brno, Czech Republic.
Tomas EckschlagerDepartment of Paediatric Haematology and Oncology, Charles University and University Hospital Motol, V Uvalu 84/1, 150 06, Prague 5, Czech Republic.
Petra PokornaDepartment of Oncology, Charles University and University Hospital Motol, V Uvalu 84/1, 150 06, Prague 5, Czech Republic.
Zbynek HegerDepartment of Chemistry and Faculty of AgriSciences, Mendel University in Brno, Zemedelska 1, 613 00, Brno, Czech Republic.
Vojtech AdamDepartment of Chemistry and Faculty of AgriSciences, Mendel University in Brno, Zemedelska 1, 613 00, Brno, Czech Republic. vojtech.adam@mendelu.cz.
Brno University of Technology · CZCentral European Institute of Technology · CZCentro de Investigaciones Biológicas Margarita Salas · ESCharles University · CZInstituto de Biomedicina y Biotecnología de Cantabria · ESMendel University in Brno · CZUniversidad de Cantabria · ESUniversity Hospital in Motol · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metallothionein-3 has poorly characterized functions in neuroblastoma. Cisplatin-based chemotherapy is a major regimen to treat neuroblastoma, but its clinical efficacy is limited by chemoresistance. We investigated the impact of human metallothionein-3 (hMT3) up-regulation in neuroblastoma cells and the mechanisms underlying the cisplatin-resistance. We confirmed the cisplatin-metallothionein complex formation using mass spectrometry. Overexpression of hMT3 decreased the sensitivity of neuroblastoma UKF-NB-4 cells to cisplatin. We report, for the first time, cisplatin-sensitive human UKF-NB-4 cells remodelled into cisplatin-resistant cells via high and constitutive hMT3 expression in an in vivo model using chick chorioallantoic membrane assay. Comparative proteomic analysis demonstrated that several biological pathways related to apoptosis, transport, proteasome, and cellular stress were involved in cisplatin-resistance in hMT3 overexpressing UKF-NB-4 cells. Overall, our data confirmed that up-regulation of hMT3 positively correlated with increased cisplatin-chemoresistance in neuroblastoma, and a high level of hMT3 could be one of the causes of frequent tumour relapses.

Indexed as

AnimalsCell Line, TumorChick EmbryoCisplatinDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMetallothionein 3Neoplasm ProteinsCisplatinMetallothionein 3Neoplasm Proteins

Identifiers

PMID33750814
PMCPMC7943580
OpenAlexW3133853603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.